Maxim lowered the firm’s price target on Nexalin Technology (NXL) to $2 from $4 and keeps a Buy rating on the shares. The firm is citing its lower revenue estimates and a slightly longer regulatory pathway regarding the Gen-2 SYNC console for Alzheimer’s disease than expected, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NXL: